title: In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM).
abstract: Type 2 diabetes mellitus is associated with elevated level of oxidative stress, which is one of the most important factors responsible for the development of chronic complications of this disease. Moreover, it was shown that diabetic patients had increased level of oxidative DNA damage and decreased effectiveness of DNA repair. These changes may be associated with increased risk of cancer in T2DM patients, since DNA damage and DNA repair play a pivotal role in malignant transformation. It was found that gliclazide, an oral hypoglycemic drug with antioxidant properties, diminished DNA damage induced by free radicals. Therefore, the aim of the present study was to evaluate the in vitro impact of gliclazide on: (i) endogenous basal and oxidative DNA damage, (ii) DNA damage induced by hydrogen peroxide and (iii) the efficacy of DNA repair of such damage. DNA damage and DNA repair in peripheral blood lymphocytes of 30 T2DM patients and 30 non-diabetic individuals were evaluated by alkaline single cell electrophoresis (comet) assay. The extent of oxidative DNA damage was assessed by DNA repair enzymes: endonuclease III and formamidopyrimidine-DNA glycosylase. The endogenous basal and oxidative DNA damages were higher in lymphocytes of T2DM patients compared to non-diabetic subjects and gliclazide decreased the level of such damage. The drug significantly decreased the level of DNA damage induced by hydrogen peroxide in both groups. Gliclazide increased the effectiveness of DNA repair in lymphocytes of T2DM patients (93.4% (with gliclazide) vs 79.9% (without gliclazide); P< or =0.001) and non-diabetic subjects (95.1% (with gliclazide) vs 90.5% (without gliclazide); P< or =0.001). These results suggest that gliclazide may protect against the oxidative stress-related chronic diabetes complications, including cancer, by decreasing the level of DNA damage induced by reactive oxygen species.
authors.affiliation: Department of Internal Medicine, Diabetology and Clinical Pharmacology, Medical University of Lodz, Zgierz, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Sliwinska
authors.forename: Janusz
authors.initials: J
authors.lastname: Blasiak
authors.forename: Jacek
authors.initials: J
authors.lastname: Kasznicki
authors.forename: Jozef
authors.initials: J
authors.lastname: Drzewoski
mesh_terms: D000368:Aged; D002469:Cell Separation; D020552:Comet Assay; D004249:DNA Damage / Q000187:drug effects*; D004260:DNA Repair / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D005260:Female; D005907:Gliclazide / Q000494:pharmacology*; D006801:Humans; D006861:Hydrogen Peroxide / Q000633:toxicity; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D016877:Oxidants / Q000633:toxicity; D012016:Reference Values
chemical_list: D007004:Hypoglycemic Agents; D016877:Oxidants; D006861:Hydrogen Peroxide; D005907:Gliclazide